We are live on ! Find out more
TTPH

Tetraphase Pharmaceuticals, Inc.
TTPH

Delisted

TTPH was delisted on the 28th of July, 2020.

90 hedge funds and large institutions have $152M invested in Tetraphase Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 23

1% more funds holding

Funds holding: 8990 (+1)

6% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 16

11% less capital invested

Capital invested by funds: $170M → $152M (-$18.1M)

43% less call options, than puts

Call options by funds: $2.88M | Put options by funds: $5.09M

Holders
90
Holders Change
+1
Holders Change %
+1.12%
% of All Funds
2.24%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
17
Increased
27
Reduced
23
Closed
16
Calls
$2.88M
Puts
$5.09M
Net Calls
-$2.21M
Net Calls Change
-$3.38M
Name Holding Trade Value Shares
Change
Change in
Stake
VEA
51
Virtus ETF Advisers
New York
$292K +$316K +2,044 New
QIM
52
Quantitative Investment Management
Virginia
$271K +$294K +1,905 New
Wells Fargo
53
Wells Fargo
California
$268K -$279K -1,803 -49%
New York State Common Retirement Fund
54
New York State Common Retirement Fund
New York
$235K
Manulife (Manufacturers Life Insurance)
55
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$224K -$1.39K -9 -0.6%
TA
56
Teton Advisors
New York
$214K
WVP
57
Worth Venture Partners
New Jersey
$209K +$227K +1,466 New
GCP
58
GSA Capital Partners
United Kingdom
$205K +$223K +1,440 New
State of Wisconsin Investment Board
59
State of Wisconsin Investment Board
Wisconsin
$200K +$216K +1,400 New
MLICM
60
Metropolitan Life Insurance Company (MetLife)
New York
$199K +$216K +1,398 New
Two Sigma Advisers
61
Two Sigma Advisers
New York
$196K -$318K -2,055 -60%
AIG
62
American International Group
New York
$167K +$8.35K +54 +5%
Ameriprise
63
Ameriprise
Minnesota
$162K +$176K +1,140 New
TI
64
Trexquant Investment
Connecticut
$156K -$53.8K -348 -24%
AQR Capital Management
65
AQR Capital Management
Connecticut
$155K +$168K +1,088 New
VOYA Investment Management
66
VOYA Investment Management
Georgia
$147K +$24K +155 +18%
VKH
67
Virtu KCG Holdings
New York
$147K +$159K +1,029 New
State Board of Administration of Florida Retirement System
68
State Board of Administration of Florida Retirement System
Florida
$142K +$1.54K +10 +1%
Axa
69
Axa
France
$132K +$143K +925 New
T. Rowe Price Associates
70
T. Rowe Price Associates
Maryland
$120K
GW
71
GW & Wade
Massachusetts
$107K
MCM
72
Manchester Capital Management
Vermont
$107K
Russell Investments Group
73
Russell Investments Group
United Kingdom
$103K -$383K -2,478 -77%
Legal & General Group
74
Legal & General Group
United Kingdom
$75K
Bank of America
75
Bank of America
North Carolina
$35K -$51.5K -333 -57%

TTPH Hedge Fund Activity: Q2 2017 in Review

90 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q2 2017, worth a combined $152M — down 11% from $170M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new TTPH positions and 16 closed out — a net gain of 1 holder — while 27 added to existing stakes and 23 trimmed.

The largest buyer was Numeric Investors, adding an estimated $5.43M. The largest seller was Acadian Asset Management, cutting an estimated $1.95M.

  • 90 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q2 2017, up from 89 in Q1 2017.
  • Funds reported $152M of Tetraphase Pharmaceuticals, Inc. stock for Q2 2017, down 11% quarter-over-quarter.
  • 17 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q2 2017 and 16 closed out, a net change of +1 holder.
  • The largest Tetraphase Pharmaceuticals, Inc. buyer in Q2 2017 was Numeric Investors, an estimated $5.43M added.
  • The largest Tetraphase Pharmaceuticals, Inc. seller in Q2 2017 was Acadian Asset Management, an estimated $1.95M sold.

Based on aggregated 13F filings for Q2 2017.